KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Depreciation and Depletion (2018 - 2025)

Historic Depreciation and Depletion for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $1.5 million.

  • Castle Biosciences' Depreciation and Depletion rose 2135.54% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 3269.93%. This contributed to the annual value of $4.9 million for FY2024, which is 4745.25% up from last year.
  • Per Castle Biosciences' latest filing, its Depreciation and Depletion stood at $1.5 million for Q3 2025, which was up 2135.54% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Depreciation and Depletion registered a high of $1.5 million during Q3 2025, and its lowest value of $233000.0 during Q1 2021.
  • Its 5-year average for Depreciation and Depletion is $861368.4, with a median of $792000.0 in 2023.
  • Per our database at Business Quant, Castle Biosciences' Depreciation and Depletion soared by 27058.82% in 2021 and then skyrocketed by 2135.54% in 2025.
  • Over the past 5 years, Castle Biosciences' Depreciation and Depletion (Quarter) stood at $442000.0 in 2021, then surged by 41.86% to $627000.0 in 2022, then surged by 51.99% to $953000.0 in 2023, then soared by 49.84% to $1.4 million in 2024, then grew by 7.84% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.5 million for Q2 2025, and $1.4 million during Q1 2025.